Définition
Lipoprotein(a) is an LDL-like particle with an additional apolipoprotein(a) attached, giving it enhanced pro-atherogenic and pro-thrombotic properties. Levels are approximately 80–90% genetically determined and do not change with diet or exercise. Elevated Lp(a) is a major independent cardiovascular risk factor that everyone should measure at least once.
Lp(a) was identified in 1963 but was largely ignored by mainstream cardiology for decades because standard lifestyle interventions don't lower it. The biology: Lp(a) is an LDL particle with an attached apolipoprotein(a) — a protein structurally similar to plasminogen (which dissolves blood clots). This structural similarity means Lp(a) interferes with normal fibrinolysis, contributing to clot formation. It also enters the arterial wall and accelerates atherosclerosis.
The critical point: Lp(a) is 80–90% genetically determined. It is set by an individual's LPA gene variants and remains remarkably stable throughout life. Diet, exercise, lifestyle modifications, and most lipid-modifying interventions do not meaningfully change it. This is why Lp(a) needs to be measured just once — if it is normal, you don't need to track it. If elevated, it becomes a persistent risk factor requiring aggressive management of all other modifiable cardiovascular risks.
Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) is found in approximately 20% of the population and confers a 2–4x increased risk of cardiovascular events. Very high levels (above 180 mg/dL) carry risks comparable to familial hypercholesterolemia. It is strongly heritable — first-degree relatives of individuals with elevated Lp(a) should also test.
Women's Lp(a) tends to be slightly lower in the reproductive years and rises modestly after menopause (estrogen has a small suppressive effect). A woman with elevated Lp(a) entering perimenopause has a particularly high need for aggressive management of all modifiable cardiovascular risk factors: optimizing ApoB to tighter targets (below 60 mg/dL), blood pressure, HbA1c, hs-CRP, and maintaining high cardiorespiratory fitness through training.
Emerging targeted Lp(a)-lowering therapies are in late-stage clinical trials but not yet broadly available. For now, the intervention remains aggressive management of everything else.
Termes associés
Ava Longevity · Built on the Ava Method · MMXXV